within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AD10_DrotrecoginAlfaActivated;

model DrotrecoginAlfaActivated
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.0833333333333334e-05,
    adminDuration = 600,
    adminMass = 24 / 1000000,
    adminCount = 1,
    Vd = 0.014,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.017,
    k12 = 5.555555555555556e-06,
    k21 = 5.555555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>DrotrecoginAlfaActivated</td></tr><tr><td>ATC code:</td><td>B01AD10</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>24</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>14</td><td>L</td></tr>
    <tr><td>clearance:</td><td>39</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Drotrecogin alfa (activated) is a recombinant form of human activated protein C, previously used for the treatment of severe sepsis with high risk of death. It acts by exhibiting antithrombotic, profibrinolytic and anti-inflammatory properties. The drug was withdrawn from the market due to lack of demonstrated efficacy and concerns about safety, particularly bleeding risk.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with severe sepsis treated with intravenous drotrecogin alfa (activated).</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AD10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end DrotrecoginAlfaActivated;
